14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $14.58 $20.11 Thursday, 2nd May 2024 DNLI stock ended at $16.81. This is 4.02% more than the trading day before Wednesday, 1st May 2024. During the day the stock fluctuated 6.41% from a day low at $15.92 to a day high of $16.94.
90 days $14.58 $23.52
52 weeks $14.58 $33.31

Historical Denali Therapeutics Inc. prices

Date Open High Low Close Volume
Sep 27, 2023 $21.51 $21.66 $21.21 $21.53 495 978
Sep 26, 2023 $21.98 $22.54 $21.34 $21.39 595 174
Sep 25, 2023 $22.07 $22.29 $21.58 $21.99 568 092
Sep 22, 2023 $22.54 $22.91 $22.09 $22.15 521 631
Sep 21, 2023 $22.01 $22.53 $21.90 $22.49 704 051
Sep 20, 2023 $22.09 $22.47 $21.92 $22.22 661 156
Sep 19, 2023 $22.24 $22.25 $21.57 $22.09 1 123 370
Sep 18, 2023 $23.28 $23.79 $22.15 $22.29 767 182
Sep 15, 2023 $24.17 $24.35 $23.28 $23.55 1 814 895
Sep 14, 2023 $23.97 $24.58 $23.76 $24.17 651 899
Sep 13, 2023 $24.33 $24.51 $23.86 $23.90 522 104
Sep 12, 2023 $23.88 $24.31 $23.73 $24.13 411 932
Sep 11, 2023 $23.97 $24.07 $23.55 $23.93 494 067
Sep 08, 2023 $24.20 $25.17 $23.91 $23.98 941 315
Sep 07, 2023 $24.53 $24.56 $23.97 $24.18 775 723
Sep 06, 2023 $24.57 $24.98 $23.69 $24.70 772 101
Sep 05, 2023 $23.27 $24.21 $23.27 $23.84 930 652
Sep 01, 2023 $23.29 $23.62 $23.10 $23.31 561 055
Aug 31, 2023 $23.31 $23.32 $22.86 $23.09 629 770
Aug 30, 2023 $22.89 $23.33 $22.82 $23.33 536 211
Aug 29, 2023 $22.79 $23.06 $22.52 $22.94 360 824
Aug 28, 2023 $22.99 $23.23 $22.25 $22.77 494 389
Aug 25, 2023 $22.33 $23.05 $22.18 $23.02 457 520
Aug 24, 2023 $22.82 $22.82 $21.95 $22.32 515 695
Aug 23, 2023 $23.22 $23.56 $22.70 $22.76 556 675
Click to get the best stock tips daily for free!

About Denali Therapeutics Inc.

Denali Therapeutics. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ... DNLI Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT